Vaxart Inc (NASDAQ:VXRT) Director Armistice Capital, Llc sold 9,385,386 shares of the firm's stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $8.29, for a total value of $77,804,849.94. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Armistice Capital, Llc also recently made the following trade(s):
- On Friday, June 26th, Armistice Capital, Llc sold 18,226,667 shares of Vaxart stock. The stock was sold at an average price of $10.38, for a total value of $189,192,803.46.
- On Wednesday, June 3rd, Armistice Capital, Llc sold 400,000 shares of Vaxart stock. The shares were sold at an average price of $2.77, for a total value of $1,108,000.00.
- On Monday, June 1st, Armistice Capital, Llc sold 200,000 shares of Vaxart stock. The shares were sold at an average price of $2.74, for a total value of $548,000.00.
- On Wednesday, May 27th, Armistice Capital, Llc sold 200,000 shares of Vaxart stock. The stock was sold at an average price of $2.61, for a total value of $522,000.00.
- On Monday, May 18th, Armistice Capital, Llc sold 650,000 shares of Vaxart stock. The stock was sold at an average price of $2.86, for a total value of $1,859,000.00.
- On Thursday, May 14th, Armistice Capital, Llc sold 834,669 shares of Vaxart stock. The shares were sold at an average price of $3.02, for a total value of $2,520,700.38.
- On Friday, May 8th, Armistice Capital, Llc sold 100,000 shares of Vaxart stock. The stock was sold at an average price of $2.52, for a total value of $252,000.00.
- On Wednesday, May 6th, Armistice Capital, Llc sold 50,000 shares of Vaxart stock. The stock was sold at an average price of $2.58, for a total value of $129,000.00.
- On Monday, May 4th, Armistice Capital, Llc sold 957,469 shares of Vaxart stock. The stock was sold at an average price of $2.65, for a total value of $2,537,292.85.
- On Thursday, April 30th, Armistice Capital, Llc sold 4,434,296 shares of Vaxart stock. The shares were sold at an average price of $2.96, for a total value of $13,125,516.16.
Shares of VXRT traded up $1.36 during midday trading on Tuesday, hitting $8.85. 93,641,140 shares of the company's stock traded hands, compared to its average volume of 13,223,815. Vaxart Inc has a 1 year low of $0.25 and a 1 year high of $14.30. The firm's fifty day moving average is $3.08 and its 200-day moving average is $1.80. The company has a current ratio of 4.52, a quick ratio of 4.52 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $596.44 million, a price-to-earnings ratio of -10.29 and a beta of 0.10.
Vaxart (NASDAQ:VXRT) last issued its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. Vaxart had a negative return on equity of 94.20% and a negative net margin of 252.86%. The firm had revenue of $2.90 million during the quarter, compared to analyst estimates of $2.80 million. On average, equities research analysts anticipate that Vaxart Inc will post -0.19 EPS for the current year.
Several equities research analysts have recently weighed in on the company. BidaskClub upgraded Vaxart from a "hold" rating to a "buy" rating in a report on Tuesday. Zacks Investment Research raised Vaxart from a "sell" rating to a "hold" rating in a research report on Friday. ValuEngine cut Vaxart from a "buy" rating to a "hold" rating in a research report on Monday, June 1st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of Vaxart in a research report on Wednesday, May 13th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Vaxart has a consensus rating of "Buy" and a consensus target price of $4.75.
Institutional investors and hedge funds have recently modified their holdings of the company. Strategic Wealth Management Group LLC purchased a new stake in shares of Vaxart during the 1st quarter valued at $28,000. Bank of New York Mellon Corp purchased a new position in Vaxart in the 1st quarter worth $74,000. Harvest Investment Services LLC purchased a new position in Vaxart in the 1st quarter worth $88,000. Geode Capital Management LLC raised its stake in Vaxart by 656.7% in the 1st quarter. Geode Capital Management LLC now owns 338,442 shares of the biotechnology company's stock worth $599,000 after acquiring an additional 293,713 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. purchased a new position in Vaxart in the 1st quarter worth $885,000. Hedge funds and other institutional investors own 40.98% of the company's stock.
About Vaxart
Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.
Read More: What is the Shanghai Stock Exchange Composite Index?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
The Next 5 Retailers on the Edge of Bankruptcy
Through no fault of theirs, the novel coronavirus has put some retailers on the edge of bankruptcy. And as you’ve seen, many have fallen over that edge including iconic names like Nieman Marcus, J.C. Penney and J.Crew.
In fact, according to the American Bankruptcy Institute, there were 560 commercial Chapter 11 filings in April. That was a 26% increase over last year. And executive director, Amy Quakenboss, suggests that there are more to come.
“As financial challenges continue to escalate amid this crisis,” observes Quakenboss, “bankruptcy is sure to offer a financial safe harbor from the economic storm.”
With no revenue walking through the door, many retailers are seeing a semblance of revenue from e-commerce sales. But for some retailers, the shutdown is more impactful because they didn’t have a strong e-commerce structure. That means that they rely more than others on brick-and-mortar sales.
The real question now is will there really be the pent-up demand that some analysts still swear is just waiting to be unleashed. It may indeed exist. Time will tell. But time is not a commodity many of these retailers have. And we’ve identified five retailers for which the clock is not in their favor.
View the "The Next 5 Retailers on the Edge of Bankruptcy".
